FDA mulls additional action on anemia drugs

The FDA is considering additional action to improve the safe use of anemia drugs after reviewing new studies that "show more rapid tumor growth or shortened survival" in patients with certain types of cancers. The agency said it is looking into additional risk information provided by Amgen, maker of Epogen and Aranesp, and Procrit developer Johnson & Johnson.

View Full Article in:

Forbes · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ